Get the Stockscreener App
1.32
0.75%
-0.01
After Hours:
1.35
0.03
+2.27%
Akebia Therapeutics Inc stock is traded at $1.32, with a volume of 1.29M.
It is down -0.75% in the last 24 hours and down -14.84% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.33
Open:
$1.32
24h Volume:
1.29M
Relative Volume:
0.53
Market Cap:
$279.68M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-2.5385
EPS:
-0.52
Net Cash Flow:
$-23.38M
1W Performance:
+0.76%
1M Performance:
-14.84%
6M Performance:
-27.87%
1Y Performance:
+15.79%
1-Day Range:
$1.30
$1.37
1-Week Range:
$1.29
$1.37
52-Week Range:
$0.7801
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Chartwell Partners Recruits CFO for Akebia Therapeutics - Hunt Scanlon Media
Alerce Investment Management L.P. Sells 7,457,213 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Bank of New York Mellon Corp Increases Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Bank of New York Mellon Corp Boosts Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Waaree Energies, Mobikwik Systems get SEBI nod for IPO - BusinessLine
Waaree Energies & MobiKwik Get Sebi Approval for IPOs - Rediffmail
Mobikwik, Waaree Energies get green signal from SEBI to float IPOs - Moneycontrol
IDBI Capital Recommends 4 Capital Goods Stocks With Up to 24% Growth Potential – Cummins, Ador Welding, and More - Share Price India News
Stocks to buy: IDBI Capital assigns 'buy' rating to four capital goods stocks including Cummins, sees up to 24% upside | Stock Market News - Mint
Paytm, Zomato, HDFC Bank, Infosys, ICICI, Axis Bank, M&M: US investors find these stocks attractive - MSN
Paytm, Zomato, HDFC Bank, Infosys, ICICI, Axis Bank, M&M: US investors find these stocks attractive - Business Today
Cummins, Kirloskar Oil, Voltamp Transformers, Ador Welding Gets A Buy As IDBI Capital Initiates Coverage - NDTV Profit
Stocks To Watch: HDFC Bank, IIFL Finance, Nykaa, Macrotech Developers, TCS - Business Standard
Akebia Announces Approval of Vafseo® (vadadustat) in Australia a - GuruFocus.com
"A legend": Zoocie Coke Dope celebrates rapper Emtee on his birthday - Briefly News
Marathon Trading Investment Management LLC Has $54,000 Stock Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Uchenna Nwosu (knee) 'progressing well' - FantasyPros
Hot Stocks: Brokerage Insights on Bajaj Auto, Emcure Pharma, LTIMindtree, and Bajaj Finance - Cover365
Kotak initiates coverage on Emcure Pharma with 'add' rating, shares surge 5% - Moneycontrol
Emcure Pharmaceuticals shares surge over 4% after positive brokerage coverage - Business Upturn
Analyzing Ratios: Akebia Therapeutics Inc. (AKBA)’s Financial Story Unveiled - The Dwinnex
Utkarsh SFB to mull fund raising of Rs 200 cr via NCDs - Business Standard
Monitoring Akebia Therapeutics Inc. (AKBA) after recent insider movements - Knox Daily
Taking the lead: Akebia Therapeutics Inc. (AKBA) - SETE News
Jefferies adds Emcure Pharma, IndiGo in model portfolio; HDFC Bank weightage rises - Moneycontrol
US FDA Review Of Akebia’s Vafseo Informed By Roxadustat, Daprodustat Safety Concerns - Pink Sheet
TD Asset Management Inc Grows Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Acadian Asset Management LLC Sells 1,246,372 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries - Pink Sheet
HC Wainwright Reiterates “Buy” Rating for Akebia Therapeutics (NASDAQ:AKBA) - Defense World
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis - RTTNews
Akebia and U.S. Renal Care to trial Vafseo in dialysis patients - Investing.com
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis - Citizentribune
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis - StockTitan
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics to present at upcoming investor conferences - News-Medical.Net
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Up 5.9% in August - Defense World
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akebia Therapeutics to Present at Piper Sandler Healthcare Confe - GuruFocus.com
SG Americas Securities LLC Takes $34,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Here's Why You Should Consider Buying Akebia (AKBA) Stock - Yahoo Finance
Here's Why You Should Consider Buying Akebia (AKBA) Stock - Zacks Investment Research
Akebia Therapeutics to Present at Upcoming Investor Conferences - Elk Valley Times
Akebia Therapeutics to Present at Upcoming Investor Conferences - Lelezard
Akebia Therapeutics to Present at Upcoming Investor Conferences - Marketscreener.com
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):